Non-HDL cholesterol can provide a better risk estimation compared with LDL-CH, in particular in hypertriglyceridaemia combined with diabetes, the metabolic syndrome, or chronic kidney disease [34]. This evidence concerns the gene C4B and metabolic syndrome.